Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Cost of Revenue (2016 - 2026)

Anika Therapeutics has reported Cost of Revenue over the past 17 years, most recently at $10.6 million for Q1 2026.

  • Quarterly Cost of Revenue fell 7.59% to $10.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $48.1 million through Mar 2026, up 6.15% year-over-year, with the annual reading at $49.0 million for FY2025, 11.62% up from the prior year.
  • Cost of Revenue was $10.6 million for Q1 2026 at Anika Therapeutics, down from $11.4 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $17.5 million in Q3 2022 and troughed at -$8.7 million in Q4 2023.
  • The 5-year median for Cost of Revenue is $12.2 million (2025), against an average of $10.7 million.
  • Year-over-year, Cost of Revenue crashed 137.1% in 2022 and then surged 255.4% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at -$6.6 million in 2022, then tumbled by 32.15% to -$8.7 million in 2023, then surged by 255.4% to $13.5 million in 2024, then decreased by 15.14% to $11.4 million in 2025, then dropped by 7.18% to $10.6 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Cost of Revenue are $10.6 million (Q1 2026), $11.4 million (Q4 2025), and $12.2 million (Q3 2025).